2014-03-01 03:01 AM
STOCKHOLM--(BUSINESS WIRE)--Feb 28, 2014--Regulatory News:
The total number of shares in Elekta (STO:EKTAB) as of February 28, 2014, amounts to 382,828,564 divided between 14,250,000 A-shares and 368,578,564 B-shares.
The increase of 205 new B-shares is attributable to the conversion of shares within the framework of the 2012/17 convertible bond.
One A-share entitles the holder to ten votes and one B-share to one vote.
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 18.00 CET on February 28, 2014.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO: EKTAB. Website: www.elekta.com.
This information was brought to you by Cision http://news.cision.com
CONTACT: Elekta AB
Johan Andersson, Director Investor Relations
Tel: +46?702?100 451
Tobias Bulow, Director Financial Communication
Tel: +46?722?215 017
KEYWORD: EUROPE SWEDEN
INDUSTRY KEYWORD: HEALTH ONCOLOGY RADIOLOGY
Copyright Business Wire 2014
PUB: 02/28/2014 12:10 PM/DISC: 02/28/2014 12:10 PM